Glaab W E, Risinger J I, Umar A, Barrett J C, Kunkel T A, Tindall K R
Laboratory of Environmental Carcinogenesis and Mutagenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA.
Carcinogenesis. 1998 Nov;19(11):1931-7. doi: 10.1093/carcin/19.11.1931.
Although the resistance to the cytotoxic response of certain DNA damaging agents has been well characterized in cells deficient in mismatch repair, little is known about how such resistance affects mutagenesis. Using human cancer cell lines defective in mismatch repair (MMR) and complementary cell lines in which the MMR defects were corrected by chromosome transfer, we present the cytotoxic effect and the mutagenic response at the hypoxanthine-guanine phosphoribosyl transferase (HPRT) locus following exposure to the chemotherapeutic agent, 6-thioguanine (6-TG). Upon exposure to 6-TG, there was a differential cytotoxic response. The MMR-deficient cells were resistant to 6-TG exposure up to 5 microM, whereas the MMR-proficient cell lines were significantly more sensitive at the same levels of exposure. Furthermore, the mutagenic response at HPRT induced by 6-TG was substantially increased in the MMR-deficient lines relative to the MMR-proficient cell lines. These findings support the notion that cytotoxicity to 6-TG is mediated through functional MMR and that resistance to the cytotoxic effects of 6-TG is directly associated with an increase in induced mutations in MMR-defective cells. These data suggest that the use of 6-TG as a chemotherapeutic agent may result in the selection of MMR-defective cells, thereby predisposing the patient to an increased risk for developing secondary tumors.
尽管在错配修复缺陷的细胞中,对某些DNA损伤剂的细胞毒性反应抗性已得到充分表征,但对于这种抗性如何影响诱变却知之甚少。我们使用错配修复(MMR)缺陷的人类癌细胞系以及通过染色体转移纠正MMR缺陷的互补细胞系,呈现了暴露于化疗药物6-硫鸟嘌呤(6-TG)后,次黄嘌呤-鸟嘌呤磷酸核糖转移酶(HPRT)位点的细胞毒性作用和诱变反应。暴露于6-TG后,出现了不同的细胞毒性反应。MMR缺陷细胞对高达5 microM的6-TG暴露具有抗性,而MMR功能正常的细胞系在相同暴露水平下则明显更敏感。此外,相对于MMR功能正常的细胞系,6-TG在MMR缺陷细胞系中诱导的HPRT诱变反应大幅增加。这些发现支持了以下观点:对6-TG的细胞毒性是通过功能性MMR介导的,并且对6-TG细胞毒性作用的抗性与MMR缺陷细胞中诱导突变的增加直接相关。这些数据表明,使用6-TG作为化疗药物可能会导致选择MMR缺陷细胞,从而使患者患继发性肿瘤的风险增加。